Colonial Trust Advisors’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$77.8K Sell
200
-36
-15% -$14.4K 0.01% 318
2026
Q2
$91.3K Buy
236
+36
+18% +$13.4K 0.01% 292
2026
Q1
$58.6K Sell
200
-69
-26% -$22.7K ﹤0.01% 332
2025
Q4
$94.3K Hold
269
– – 0.01% 273
2025
Q3
$86.9K Hold
269
– – 0.01% 277
2025
Q2
$105K Hold
269
– – 0.01% 257
2025
Q1
$117K Hold
269
– – 0.01% 249
2024
Q4
$99.2K Hold
269
– – 0.01% 244
2024
Q3
$140K Hold
269
– – 0.01% 228
2024
Q2
$146K Sell
269
-3
-1% -$1.59K 0.01% 207
2024
Q1
$141K Sell
272
-9
-3% -$4.48K 0.01% 210
2023
Q4
$133K Sell
281
-150
-35% -$69.4K 0.01% 211
2023
Q3
$188K Hold
431
– – 0.02% 188
2023
Q2
$191K Sell
431
-1
-0.2% -$461 0.02% 194
2023
Q1
$199K Sell
432
-1
-0.2% -$476 0.02% 189
2022
Q4
$222K Buy
433
+169
+64% +$85.8K 0.03% 193
2022
Q3
$120K Buy
+264
New +$126K 0.02% 208

Other funds holding ELV

Colonial Trust Advisors's ELV Position: Q3 2026 in Review

Colonial Trust Advisors reduced its Elevance Health (ELV) stake by 15% in Q3 2026, selling an estimated $14.4K and leaving 200 shares worth $77.8K. The position accounts for 0.01% of the portfolio, ranked #318.

Colonial Trust Advisors first reported a position in ELV in Q3 2022 and has held it in 17 quarters since. The position peaked at $222K in Q4 2022. 1,626 funds tracked by Wall St. Rank hold ELV as of Q3 2026.

  • Colonial Trust Advisors held 200 shares of Elevance Health worth $77.8K as of Q3 2026.
  • Colonial Trust Advisors sold 36 Elevance Health shares in Q3 2026, an estimated $14.4K.
  • Elevance Health made up 0.01% of Colonial Trust Advisors's portfolio in Q3 2026, its #318 holding.
  • Colonial Trust Advisors first reported a position in Elevance Health in Q3 2022 and has held it in 17 quarters since.
  • Colonial Trust Advisors's Elevance Health position peaked at $222K in Q4 2022.
  • 1,626 funds tracked by Wall St. Rank held Elevance Health as of Q3 2026.

Based on Colonial Trust Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.